Translate this page into:
F-18 PSMA Uptake in Male Breast Cancer during Restaging Evaluation of Carcinoma Prostate
Address for correspondence: Dr. Anand Zade, Department of Nuclear Medicine, Apollo Hospitals, Sector 23, CBD Belapur, Navi Mumbai - 400 614, Maharashtra, India. E-mail: dr_anandzade@yahoo.com
-
Received: ,
Accepted: ,
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
This article was originally published by Wolters Kluwer - Medknow and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Fluorine-18 prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography scan is widely used for restaging of prostate cancer. We present a case where false-positive PSMA uptake was seen in metachronous carcinoma breast during restaging workup of carcinoma prostate.
Keywords
Carcinoma breast
prostate-specific membrane antigen pitfall
prostate-specific membrane antigen positron emission tomography-computed tomography
A 77-year-old gentleman with carcinoma prostate, post orchiectomy with raised serum PSA level of 39.1 ng/ml was referred for fluorine-18 prostate-specific membrane antigen positron emission tomography-computed tomography (PSMA PET-CT) scan as a part of restaging work up [Figure 1a-e]. Maximum intensity projected (MIP) image (a), axial CT (b), and axial fused images (c) showed increased tracer uptake in both lobes of prostate (arrows) consistent with disease recurrence. Increased PSMA uptake was also noted in the soft tissue mass in right breast parenchyma (arrowhead) in MIP (A), axial CT (d), and axial fused images (e). Considering the fact that breast metastasis from carcinoma prostate is rare and that PSMA is also expressed in neovasculature of nonprostatic malignancies, the possibility of metachronous carcinoma right breast was contemplated. Histology of biopsy from the right breast mass [Figure 2a-e] revealed infiltrating ductal carcinoma of intermediate nuclear grade (a). On immunohistochemistry, the tumor cells expressed Pan CK (B) and CK7 (a). The cells were immunonegative for CK20 (d) and PSA (e).
Patients with prostate cancer who are on hormonal therapy often present with gynecomastia which may be unilateral or bilateral. It is important to differentiate unilateral gynecomastia from primary breast malignancy and metastasis of prostate cancer as it has implications in treatment as well as prognosis.[123] Since PSMA is expressed in gynecomastia as well as primary breast carcinoma, it is not always possible to differentiate these clinical entities noninvasively on a PSMA PET-CT scan.[45678] Biopsy with immunohistochemistry (IHC) for hormonal receptor and PSA expression not only helps in diagnosis but also guides further hormonal treatment. PSA staining differentiates primary breast carcinoma from metastatic prostatic carcinoma.[910] In the present case, PSA staining was negative suggestive of metachronous breast carcinoma. The knowledge of this imaging pitfall is crucial to avoid misinterpretation and guide appropriate treatment.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient (s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References
- Gynecomastia in patients with prostate cancer: A systematic review. PLoS One. 2015;10:e0136094..
- [Google Scholar]
- Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: The role of tamoxifen and radiotherapy. J Urol. 2005;174:2197-203.
- [Google Scholar]
- A synchronous diagnosis of metastatic male breast cancer and prostate cancer. J Investig Med High Impact Case Rep. 2019;7:2324709619847230..
- [Google Scholar]
- False positive uptake in bilateral gynecomastia on 68Ga-PSMA PET/CT scan. Clin Nucl Med. 2017;42:e412-4.
- [Google Scholar]
- Synchronous detection of male breast cancer and prostatic cancer in a patient with suspected prostatic carcinoma on 68Ga-PSMA PET/CT imaging. Clin Nucl Med. 2018;43:431-2.
- [Google Scholar]
- 18F-PSMA 1007 uptake in a man with metastatic breast cancer. Clin Nucl Med. 2020;45:e276-8.
- [Google Scholar]
- Radiolabelled PSMA PET/CT in breast cancer. A systematic review. Nucl Med Rev Cent East Eur. 2020;23:32-5.
- [Google Scholar]
- Prostate-Specific Membrane Antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017;34:479-90.
- [Google Scholar]
- Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol. 2010;5:63..
- [Google Scholar]
- Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report. BMC Cancer. 2018;18:1282..
- [Google Scholar]